Oleksiak MF, Churchill GA, Crawford DL
Disclosures: Fatima DAHBOUL: Nothing to Disclose, JIHAN SUN: Nothing to Disclose, Benjamin Buchard: Nothing to Disclose, Delphine Weil-Verhoeven: Nothing to Disclose, Vincent Di Martino: Nothing to Disclose, Aicha Demidem: Nothing to Disclose, Armand Abergel: Nothing to Disclose 1875 RADIOMICS-BASED PREDICTION OF HCC RESPONSE TO ATEZOLIZUMAB/BEVACIZUMAB Isaac Israel Rodriguez Salazar 1 Andreas Teufel 1 Abhinay Vellala 1 Timo Itzel 1 Jimmy Daza 1 Michael Vcha 1 Manuel Debic 2 De-Hua Chang 3 Michael Dill 2 Max Seidensticker 4 Gerd Oswald Stefan Schnberg 1 Lukas Mller 5 Julia Mayerle 4 Stefan Munker 4 Peter Galle 5 Arndt Weinmann 5 Dietmar Tamandl 6 Matthias Pinter 6 Marino Venerito 7 Matthias Ebert 1 Matthias Froelich 1 Maciej Pech 7 Friedrich Sinner 7 Bernhard Scheiner 6 , 1 Medical Faculty Mannheim, 2 Medical Faculty Heidelberg, 3 Cantonal Hospital of Lucerne, 4 LMU Munich, 5 University Medical Center Mainz, 6 Medical Faculty Vienna, 7 Magdeburg University Background: Atezolizumab/ bevacizumab has emerged as a breakthrough therapy for advanced hepatocellular carcinoma (HCC)
Removal of heavy metal ions using a new high performance nanofiltration membrane modified with curcumin boehmite nanoparticles
Activation of FFA3 receptors on vagus nerve cells can result in the activation of various neurons in the CNS, including dynamic regulation of hypothalamic neuronal circuitry (287)
First, GPX4 reduces the toxic lipid peroxides to non-toxic lipid alcohols by oxidizing its active site, selenol (Se-H), to selenenic acid (Se-OH)
